Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).

Abstract

A mouse monoclonal antibody (MAb17-1A) (IgG2A) against colorectal carcinoma cells was used to treat patients with metastatic disease. Major direct effector functions of MAb seem to be ADCC (antibody dependent cellular cytotoxicity), CDC (complement dependent cytolysis) and apoptosis ('programmed cell death'). Thus, a high tumor cell saturation of the MAb… (More)

Topics

Cite this paper

@article{Mellstedt1991TherapyOC, title={Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).}, author={H»kan Mellstedt and Jan Erik Fr{\"o}din and Peter Ragnhammar and Giuseppe V Masucci and Anna Ljungberg and A L Hjelm and Jonas H. Fagerberg and Christina Lindemalm and Anders Osterborg and Peter J Wers{\"a}ll}, journal={Acta oncologica}, year={1991}, volume={30 8}, pages={923-31} }